Start the conversation
I've been watching the biotech and information systems industries closely as strong Q2 earnings season leaders. These sectors have been carrying a bulk of recent stock rallies, bolstering major market indexes higher.
And today, I'm bringing you a Fast Profits options play tapped into two avenues of Big Tech profits.
This company doesn't just solve big problems for other large-cap tech leaders; it's a full-service cloud solutions platform, managing operations from the seed of an idea all the way to the realized benefit.
For those of us who aren't fintech whizzes, this is basically some of the highest-quality service you can get in this industry. I like to think of this company as a "supercharged" Quicken Inc. – typically the posterchild of cloud computing solutions among tech companies.
It recently released second-quarter earnings at $0.15 per share, exceeding expectations by a whopping 150%. This will be the fourth earnings beat in a row for this "next big thing" innovator… And with businesses across the globe preparing to hunker down into semi-permanent, virtual business models, given that the coronavirus is still running rampant, demand for today's Fast Profits stock to trade is only going to keep climbing.
See the full trade details in this, my latest edition of Fast Profits with Money Morning…
Could This Be the End of COVID-19?
Action to take No. 1: Buy shares of Model N Inc. (NYSE: MODN) using a limit order of $43.
Action to take No. 2: Buy to open MODN Feb. 19, 2021 $45 calls (MODN210219C00045000) using a limit order of $5.10.
One key takeaway from today's Fast Profits: The biotech sector will be minting loads of profitable opportunities in the coming months.
It's something we can clearly see in the above coverage of Model N, tackling the surging demand from the administrative side of the industry.
But there's one other clear path to profits emerging from the biotech sector now, a frontrunner in the race to create a vaccine for COVID-19.
In fact, the FDA just granted the "Super Vaccine" a fast track designation and backed the initiative with $483 million to help get the drug to market fast.
And this won't just mean a possible end to a grueling, six-month pandemic…
It could also ignite a 58,300% revenue surge.
About the Author
Chris Johnson is a highly regarded equity and options analyst who has spent much of his nearly 30-year market career designing and interpreting complex models to help investment firms transform millions of data points into impressive gains for clients.
At heart Chris is a quant - like the "rocket scientists" of investing - with a specialty in applying advanced mathematics like stochastic calculus, linear algebra, differential equations, and statistics to Wall Street's data-rich environment.
He began building his proprietary models in 1998, analyzing about 2,000 records per day. Today, that database, which Chris designed and coded from scratch, analyzes a staggering 700,000 records per day. It's the secret behind his track record.
Chris holds degrees in finance, statistics, and accounting. He worked as a licensed broker for 11 years before taking on the role of Director of Quantitative Analysis at a big-name equity and options research firm for eight years. He recently served as Director of Research of a Cleveland-based investment firm responsible for hundreds of millions in AUM. He is also the Founder/CIO of ETF Advisory Research Partners since 2007, noted for its groundbreaking work in Behavioral Valuation systems. Their research is widely read by leaders in the RIA business.
Chris is ranked in the top 99.3% of financial bloggers and top 98.6% of overall experts by TipRanks, the track record registry of financial analysts dating back to January 2009.
He is a frequent commentator on financial markets for CNBC, Fox, Bloomberg TV, and CBS Radio and has been featured in Barron's, USA Today, Newsweek, and The Wall Street Journal, and numerous books.
Today, Chris is the editor of Night Trader and Straight-Up Profits. He also contributes to Money Morning as the Quant Analysis Specialist.